Compare iShares Bitcoin Trust (IBIT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Neurocrine Biosciences Inc — how do they compare? iShares Bitcoin Trust trades at $46.77 (market cap $67.31B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: iShares Bitcoin Trust is far larger — about 4.7× Neurocrine Biosciences Inc's market cap, and iShares Bitcoin Trust is more actively traded (56,154,544 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and Neurocrine Biosciences Inc for 23 Days on average.
| IBIT | NBIX | |
|---|---|---|
Market Cap | $67.31B | $14.36B |
Volume | 56,154,544 | 1,237,180 |
Sector | Crypto-linked | Health |
52-Week High | $68.74 | $185.50 |
52-Week Low | $33.29 | $123.10 |
Typical Hold Time | 40 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $47.21, down 2.64% on the day, with technical indicators showing a bullish overall signal driven by moving averages. The stock faces immediate support at $46 and resistance at $48. Recent news highlights strong institutional interest with BlackRock's IBIT recording $196 million in daily inflows on October 1, 2026, signaling renewed investor confidence in Bitcoin-focused investment products.
The outlook remains cautiously optimistic given institutional inflows and technical strength, though the absence of traditional financial metrics like P/E and P/S limits fundamental analysis. Key risks include market volatility and regulatory uncertainty, while analyst sentiment appears mixed with technical indicators favoring bullish momentum near-term.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
